<SEC-DOCUMENT>0001213900-25-118848.txt : 20251205
<SEC-HEADER>0001213900-25-118848.hdr.sgml : 20251205
<ACCEPTANCE-DATETIME>20251205174058
ACCESSION NUMBER:		0001213900-25-118848
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251205
DATE AS OF CHANGE:		20251205

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enveric Biosciences, Inc.
		CENTRAL INDEX KEY:			0000890821
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				954484725
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-53543
		FILM NUMBER:		251554052

	BUSINESS ADDRESS:	
		STREET 1:		245 FIRST STREET RIVERVIEW II 18TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		239-302-1707

	MAIL ADDRESS:	
		STREET 1:		245 FIRST STREET RIVERVIEW II 18TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERI Holdings, Inc.
		DATE OF NAME CHANGE:	20150527

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SPATIALIZER AUDIO LABORATORIES INC
		DATE OF NAME CHANGE:	19950323

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NORTHSTRIVE FUND II LP
		CENTRAL INDEX KEY:			0002099270
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		120 NEWPORT CENTER DR
		STREET 2:		STE 250
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			926660
		BUSINESS PHONE:		9498757003

	MAIL ADDRESS:	
		STREET 1:		120 NEWPORT CENTER DR
		STREET 2:		STE 250
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			926660
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: NORTHSTRIVE FUND II LP -->
          <cik>0002099270</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, $0.01 par value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>12/03/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0000890821</issuerCik>
        <issuerName>ENVERIC BIOSCIENCES, INC.</issuerName>
        <issuerCusip>29405E505</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>245 First Street, Riverview II</com:street1>
          <com:street2>18th Floor</com:street2>
          <com:city>Cambridge</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02142</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(d)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Northstrive Fund II LP</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>25915.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>25915.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>25915.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>4.34</classPercent>
      <typeOfReportingPerson>PN</typeOfReportingPerson>
      <comments>(1) This percentage is based on 596,978 shares of Common Stock of the Issuer that were outstanding as of November 12, 2025, as reported in the Issuer's Form 10-Q filed with the U.S. Securities and Exchange Commission ("SEC") on November 14, 2025. For the avoidance of doubt, the holdings of the Reporting Persons reported herein are as of December 3, 2025. The aggregate percentage ownership of both Reporting Persons is approximately 5.01%.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Braeden Lichti</reportingPersonName>
      <citizenshipOrOrganization>Z4</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>4005.00</soleVotingPower>
        <sharedVotingPower>25915.00</sharedVotingPower>
        <soleDispositivePower>4005.00</soleDispositivePower>
        <sharedDispositivePower>25915.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>29920.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.01</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>(2) This percentage is based on 596,978 shares of Common Stock of the Issuer that were outstanding as of November 12, 2025, as reported in the Issuer's Form 10-Q filed with the SEC on November 14, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>ENVERIC BIOSCIENCES, INC.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>245 First Street, Riverview II, 18th Floor, Cambridge, MA</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>This statement is filed by:

(i) Northstrive Fund II LP, a Delaware limited partnership; and

(ii) Braeden Lichti ("Mr. Lichti").

The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."

The securities reported herein are held by Northstrive Fund II LP and Braeden Lichti. Mr. Lichti is the Manager of Northstrive Fund II LP. As such, Mr. Lichti may be deemed to beneficially own the securities held by Northstrive Fund II LP. To the extent Mr. Lichti is deemed to beneficially own such securities, Mr. Lichti disclaims beneficial ownership of these securities for all other purposes.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>120 Newport Center Drive, Suite 250
Newport Beach, CA 92660</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Northstrive Fund II LP is a Delaware corporation. Mr. Lichti is a citizen of Canada.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>The information required by Item 4(a) is set forth in Rows 5-11 of the cover page for each Reporting Person and is incorporated herein by reference for each Reporting Person.</amountBeneficiallyOwned>
        <classPercent>Northstrive Fund II LP: 4.34%
Braeden Lichti: 5.01%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>Northstrive Fund II LP: 0

Braeden Lichti: 4,005</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>Northstrive Fund II LP: 25,915

Braeden Lichti: 25,915</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>Northstrive Fund II LP: 0

Braeden Lichti: 4,005</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>Northstrive Fund II LP: 25,915

Braeden Lichti: 25,915</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>Y</notApplicableFlag>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Northstrive Fund II LP</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Braeden Lichti</signature>
        <title>Braeden Lichti, Manager</title>
        <date>12/05/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Braeden Lichti</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Braeden Lichti</signature>
        <title>Braeden Lichti</title>
        <date>12/05/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
